secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0000012208-26-000007
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad Q4 GAAP operating loss $118.9M; non-GAAP EPS down to $2.51 from $2.90
-----------------------------------------------------------------------------

- Q4 GAAP operating loss $118.9M vs income $58.4M YoY; gross margin down 140bps to 49.8%.
- Q4 non-GAAP operating income $83.0M (down 10% YoY); non-GAAP EPS $2.51 vs $2.90.
- Full-year non-GAAP operating income $311.6M vs $331.3M; EPS $9.92 vs $10.31.
- Q4 GAAP net income $720.0M vs $715.8M loss YoY driven by equity investment fair value changes.
- CEO cites geopolitical uncertainty and academic funding pressure; Stilla acquisition integrated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220826000007/0000012208-26-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220826000007/bio-20260212.htm
  HTML page:      https://secwatch.observer/filing/0000012208-26-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer